362. Paul Coletta, Co-Founder & CEO of Vero Bioscience

Today, I'm joined by Paul Coletta, co-founder & CEO of Vero Bioscience.   A predictive health company, Vero uses proteomic blood tests and proprietary AI to measure and improve organ-level aging.   In this episode, we discuss building a closed-loop health system powered by proteomics.   We also cover: - Why organ-level data beats whole-body scores - How proteomics differs from other biological age measures - Reproducibility, clinical validation, and roadmap to launch Subscribe to the podcast → insider.fitt.co/podcast  Subscribe to our newsletter → insider.fitt.co/subscribe  Follow us on LinkedIn → linkedin.com/company/fittinsider    Get on the waitlist: verobioscience.com  X (Twitter): https://x.com/Vero\_Bioscience Follow Paul: https://www.linkedin.com/in/paulcoletta Follow Vero: https://www.linkedin.com/company/vero-bioscience-inc  Eudaimonia (Health Innovation Lab) in November: https://eudemonia.net/hil/  YouTube: https://www.youtube.com/@VeroBioscience    The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com to learn more about its smart fitness ecosystem for fitness and health facilities.   Fitt Talent: https://talent.fitt.co/  Consulting: https://consulting.fitt.co/  Investments: https://capital.fitt.co/    Chapters: (00:00) Introduction (01:30) Paul's background (02:45) 11K protein measurement (04:00) Stanford technology (05:00) Scientific validation (06:00) Biological age vs. organ age (07:30) Actionability and reproducibility (10:00) Clinical validation approach (12:15) Closed-loop compass system (14:00) Organ-specific interventions (15:30) Healthspan vs. immortality (19:15) Clinical partnerships strategy (22:00) Competitive differentiation (25:00) Direct-to-consumer roadmap (27:30) Regulatory and cost challenges (28:30) Educating the market (30:00) Balancing rigor and marketing (34:00) Patient-led future (36:45) Conclusion